Valneva SEVV

Valneva SE

3.20USDD
−0.10−3.03%
At close at Mar 4, 17:55 GMT
USD
No trades
See on Supercharts

INRLF fundamentals

Key facts

Market capitalization‪519.67 M‬USD
Basic EPS (TTM)−0.05USD
Founded1999
CEOThomas Lingelbach
About

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Ownership
‪‪162.40 M‬‬
Free Float shares
‪‪135.92 M‬‬ (83.69%)
Closely held shares
‪‪26.48 M‬‬ (16.31%)
Free Float shares
‪‪135.92 M‬‬ (83.69%)
Closely held shares
‪‪26.48 M‬‬ (16.31%)
Capital structure
Market cap
‪‪519.67 M‬‬
Debt
‪‪224.07 M‬‬
Cash & equivalents
‪‪174.06 M‬‬
Enterprise value
‪‪569.68 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪519.67 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
3.18x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
3.18x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪1.10‬
‪2.20‬
‪3.30‬
‪4.40‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−90%‬
‪0%‬
‪90%‬
‪180%‬
‪270%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−70.00 M‬‬
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Development and Commercialization of Prophylactic Vaccines
By country
Period: 2023
United States
Canada
United Kingdom
Rest of World
Austria
Germany
Nordics
Other Europe
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
‪‪80.00 M‬‬
Actual
Estimate
Earnings
Next:Mar 20, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.30‬
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

INRLF does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−90.00 M‬‬
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
‪‪360.00 M‬‬
Assets
Liabilities